Director, RaaS Research Group, Research as a Service (RaaS)

Research as a Service (RaaS)

Director, RaaS Research Group

Insightful Financial Models and Research Analysis

Connect to the right investors through smart and insightful financial models and research analysis.

Equity Bottom-Up

<div>
<table class="table table-striped">
<tbody>
<tr>
<td>
<div>
<p><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank">Noxopharm (ASX:NOX) is a clinical stage drug development company with a leading drug candidate in various clinical trials at Phase II level. There is also an active drug development program developing new drug compounds. The company’s current lead drug candidate is Veyonda<sup>R</sup> which is an immunotherapy drug designed to boost the effectiveness of all three major forms of cancer treatment - immuno-oncology therapy, radiotherapy and chemotherapy. To that end, the company is engaged in three separate cancer studies – the IONIC-1 Study (Phase I/II) with Britol Myers Squibb (BMS) to see if Veyonda<sup>R</sup> can overcome resistance to nivolumab (Opdivo<sup>R</sup>) found in most solid cancers; the DAART-2 (Phase II) study to test Veyonda’s ability to achieve high rates of abscopal effect in patients with prostate, breast or lung cancers; the LuPIN (Phase I/II) testing ability of Veyonda<sup>R</sup> to boost response to the US$6b radiopharmaceutical, LuPSMA-617 (Novartis). Veyonda<sup>R</sup> also has unique anti-inflammatory properties, leading to it currently being tested in a Phase 1b trial on COVID-19 where it is being used to block the long term and often fatal outcomes of the virus. The company has also recently established a new subsidiary, Pharmorage, to build on the anti-inflammatory properties of Veyonda<sup>R</sup>.</a></p>
</div>
</td>
</tr>
</tbody>
</table>
</div>







Noxopharm (ASX:NOX) is a clinical stage drug development company with a leading drug candidate in various clinical trials at Phase II level. There is also an active drug development program developing new drug compounds. The company’s current lead drug candidate is VeyondaR which is an immunotherapy drug designed to boost the effectiveness of all three major forms of cancer treatment - immuno-oncology therapy, radiotherapy and chemotherapy. To that end, the company is engaged in three separate cancer studies – the IONIC-1 Study (Phase I/II) with Britol Myers Squibb (BMS) to see if VeyondaR can overcome resistance to nivolumab (OpdivoR) found in most solid cancers; the DAART-2 (Phase II) study to test Veyonda’s ability to achieve high rates of abscopal effect in patients with prostate, breast or lung cancers; the LuPIN (Phase I/II) testing ability of VeyondaR to boost response to the US$6b radiopharmaceutical, LuPSMA-617 (Novartis). VeyondaR also has unique anti-inflammatory properties, leading to it currently being tested in a Phase 1b trial on COVID-19 where it is being used to block the long term and often fatal outcomes of the virus. The company has also recently established a new subsidiary, Pharmorage, to build on the anti-inflammatory properties of VeyondaR.







Noxopharm (NOX) Extended Survival Options

Australia

Noxopharm Limited operates as a drug development company. The Company focuses on the field of inhibiting cancer drug resistance mechanisms. Noxopharm conducts business in Australia with offices in Melbourne and Sydney.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Noxopharm Ltd (NOX AU)

Noxopharm (NOX) Extended Survival Options

Noxopharm (ASX:NOX) is a clinical stage drug development company with a leading drug candidate in various clinical trials at Phase II level....

Research as a Service (RaaS)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)